论文部分内容阅读
目的观察沙美特罗/氟替卡松吸入粉剂(舒利迭,50μg/500μg)联合噻托溴铵(18μg/粒)治疗对慢性阻塞性肺疾病(COPD)稳定期患者的临床疗效。方法 COPD稳定期患者80例随机均分为两组,分别采用舒利迭联合噻托溴铵(沙美特罗/氟替卡松50μg/500μg和18μg,A组)和单用舒利迭(沙美特罗/氟替卡松50μg/500μg,B组)治疗,疗程均为28d。比较两组治疗前后的临床症状的改善及肺功能变化。结果两组治疗后临床症状及肺通气功能均显著改善,A组总有效率显著高于B组(92.5%vs.82.5%)(P<0.05)。治疗后,A组第1秒用力呼气容积占预计值百分比和第1秒用力呼气容积比用力肺活量均高于B组[(68.9±8.27)%vs.(59.5±7.63)%和(68.1±7.1)%vs.(63.6±4.82)%](P<0.05)。结论舒利迭联合噻托溴铵治疗COPD稳定期患者的临床疗效优于舒利迭。
Objective To observe the clinical efficacy of salmeterol / fluticasone inhalation powder (seretide, 50 μg / 500 μg) and tiotropium (18 μg / capsule) in the treatment of patients with stable chronic obstructive pulmonary disease (COPD). Methods Eighty patients with stable COPD were randomly divided into two groups. Patients were randomly divided into two groups: seretide plus tiotropium (salmeterol / fluticasone 50 μg / 500 μg and 18 μg, group A) and salmeterol alone Fluticasone 50μg / 500μg, B group) treatment, treatment were 28d. The improvement of clinical symptoms and changes of pulmonary function before and after treatment were compared between the two groups. Results The clinical symptoms and pulmonary ventilation were significantly improved after treatment in both groups. The total effective rate in group A was significantly higher than that in group B (92.5% vs 82.5%, P <0.05). After treatment, the forced expiratory volume in 1 second and the forced expiratory volume in 1 second were significantly higher in group A than those in group B (68.9 ± 8.27% vs 59.5 ± 7.63% vs 68.1 ± 7.1% vs 63.6 ± 4.82%] (P <0.05). Conclusion The clinical efficacy of sevlet in combination with tiotropium for the treatment of patients with stable COPD is superior to that of seretide.